The same system Moderna used for its COVID vaccine may also be able to help prevent HIV. Two of Moderna’s mRNA-based HIV vaccines could start human trials this week, according to a new posting in the National Institutes of Health’s clinical trial registry. The Phase I study would test the vaccines’ safety, as well as collect basic data on whether they’re inducing any kind of immunity, but would still need to go through Phases II and III to see how effective they might be.
The first mRNA-based HIV vaccine is about to start human trials
Latest News
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).